Enanta Pharmaceuticals, Inc. (ENTA) Analysts See $0.04 EPS

January 23, 2018 - By Marie Mckinney

 Enanta Pharmaceuticals, Inc. (ENTA) Analysts See $0.04 EPS
Investors sentiment increased to 1.6 in Q3 2017. Its up 0.75, from 0.85 in 2017Q2. It increased, as 9 investors sold Enanta Pharmaceuticals, Inc. shares while 31 reduced holdings. 16 funds opened positions while 48 raised stakes. 12.10 million shares or 2.87% more from 11.77 million shares in 2017Q2 were reported.
Dimensional Fund Advsrs Lp has invested 0.01% in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Moreover, Alliancebernstein Lp has 0% invested in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Weiss Multi holds 0.05% of its portfolio in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) for 30,000 shares. Blackrock, New York-based fund reported 2.25M shares. Comerica Savings Bank holds 0.01% or 15,087 shares. State Common Retirement Fund stated it has 49,418 shares. Adams Diversified Equity Fund Inc holds 0.05% or 20,000 shares in its portfolio. Moreover, Northern Trust has 0% invested in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) for 195,523 shares. Prudential Financial Incorporated accumulated 46,597 shares. Proshare Advsr Ltd Limited Liability Company has invested 0.01% in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Guggenheim Cap Ltd Co has invested 0% of its portfolio in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Schwab Charles Inv Mgmt Inc invested 0% in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). The Kentucky-based Alphamark Advsrs Ltd Liability Co has invested 0.51% in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Loomis Sayles & L P stated it has 0% in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Clarivest Asset Mngmt Lc accumulated 0.01% or 13,500 shares.

Analysts expect Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) to report $0.04 EPS on February, 14.They anticipate $0.30 EPS change or 115.38 % from last quarter’s $-0.26 EPS. ENTA’s profit would be $764,814 giving it 441.94 P/E if the $0.04 EPS is correct. After having $1.86 EPS previously, Enanta Pharmaceuticals, Inc.’s analysts see -97.85 % EPS growth. The stock increased 5.04% or $3.39 during the last trading session, reaching $70.71. About 164,848 shares traded. Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has risen 40.91% since January 23, 2017 and is uptrending. It has outperformed by 24.21% the S&P500.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Ratings Coverage

Among 5 analysts covering Enanta Pharmaceuticals Inc (NASDAQ:ENTA), 2 have Buy rating, 1 Sell and 2 Hold. Therefore 40% are positive. Enanta Pharmaceuticals Inc had 20 analyst reports since August 7, 2015 according to SRatingsIntel. Robert W. Baird maintained Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) on Monday, November 20 with “Hold” rating. The firm has “Market Perform” rating given on Thursday, April 28 by JMP Securities. The firm earned “Overweight” rating on Tuesday, August 9 by JP Morgan. RBC Capital Markets maintained Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) rating on Monday, November 20. RBC Capital Markets has “Buy” rating and $58.0 target. The rating was downgraded by Barclays Capital on Friday, October 23 to “Underweight”. The stock has “Hold” rating by Robert W. Baird on Friday, October 20. The stock has “Mkt Outperform” rating by JMP Securities on Friday, October 23. On Tuesday, January 2 the stock rating was downgraded by RBC Capital Markets to “Sector Perform”. Robert W. Baird maintained Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) on Friday, September 15 with “Hold” rating. RBC Capital Markets maintained the stock with “Buy” rating in Friday, October 20 report.

Enanta Pharmaceuticals, Inc., a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company has market cap of $1.35 billion. The company??s research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus. It has a 77.7 P/E ratio. It has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus.

More notable recent Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) news were published by: Businesswire.com which released: “Enanta Pharmaceuticals to Provide Updates on its Research and Development …” on January 05, 2018, also Seekingalpha.com with their article: “Enanta Pharmaceuticals: Updates To Thesis” published on August 06, 2017, Seekingalpha.com published: “Enanta Pharmaceuticals’ (ENTA) CEO Jay Luly on Fiscal Q3 2017 Results …” on August 08, 2017. More interesting news about Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) were released by: Seekingalpha.com and their article: “Enanta Pharmaceuticals’ (ENTA) CEO Jay Luly on Fiscal Q4 2017 Results …” published on November 21, 2017 as well as Businesswire.com‘s news article titled: “Enanta Pharmaceuticals Announces New Data Presentations on EDP-305, an FXR …” with publication date: September 27, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.